Lv1
54 积分 2024-01-04 加入
Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients
28天前
已完结
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
1个月前
已完结
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
1个月前
已完结
[Surgical treatment of primary liver cancer:a report of 10 966 cases]
1个月前
已完结
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma
1个月前
已完结
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
1个月前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
1个月前
已完结
Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study
1个月前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
1个月前
已完结
皖公网安备34019202002308
